Legal Research

This Week?s Biotech Highlights

By Jeremy Grushcow

This is the 26th edition of This Weeks’ Biotech Highlights, which means Slaw has been hosting my ramblings for exactly half a year.  Thanks!  Other things I’m thankful for:

• Takeda Canada, which opened in Mississauga in March, got the ball rolling with their Canadian business by buying back rights to a diabetes drug from Eli Lilly.
• The National Research Counsel’s IRAP program, which received a tonne of Canadian stimulus money and has been making a lot of biotech investments lately.
• LOM and BioQuest, who created some excitement about Canada’s biotech industry by announcing a new joint venture then were kind enough to talk to me about it.
• The SIFT Tax, which messed up Canada’s income trusts, but is now generating some much-needed cash for biotechs as income trusts and public LPs shop for listed companies to convert into.
• Twitter, which is still a great microblogging tool and helps me keep readers abreast of biotech news when I only have micro-time.

I’m also thankful that by the time Canadian and American Thanksgiving roll around, I’ll be able to roll out the gratitude theme for my posts again and hopefully you’ll still gobble it up.  In the meantime, check in at the Cross-Border Biotech Blog for updates on Personalized Medicine and a NOVA program on genetic testing.

Full post as published by Slaw.ca on August 24, 2009 (boomark / email).